Treatment of Metastatic Disease with Immune Checkpoint Inhibitors Nivolumab and Pembrolizumab: Effect of Performance Status on Clinical Outcomes

INTRODUCTION: Although guidelines exist for appropriate use of chemotherapy in the metastatic setting based on performance status, such recommendations are less readily available for immune checkpoint inhibitors (ICIs). We sought to determine whether there is a relationship between Eastern Cooperati...

Descripción completa

Detalles Bibliográficos
Autores principales: Wells, Leah, Cerniglia, Michael, Hall, Sarah, Jost, Audrey C., Britt, Gregory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Innovative Healthcare Institute 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153247/
https://www.ncbi.nlm.nih.gov/pubmed/35664089
http://dx.doi.org/10.36401/JIPO-22-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153247/
https://www.ncbi.nlm.nih.gov/pubmed/35664089
http://dx.doi.org/10.36401/JIPO-22-3

Ejemplares similares